This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.
Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
AMN Healthcare (AMN) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 10.30% and 3.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of 2.39% and 0.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.
Pfizer (PFE) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 21.09% and 7.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Zacks.com featured highlights include Publicis Groupe S.A., Jabil, AMN Healthcare Services and A-Mark Precious Metals
by Zacks Equity Research
Publicis Groupe S.A., Jabil, AMN Healthcare Services and A-Mark Precious Metals are part of Zacks Screen of the Week article.
Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AMN Healthcare Services (AMN) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Look Beyond Profit, Pick These 4 Stocks With Rising Cash Flows
by Moumita C. Chattopadhyay
Cash is the most indispensable factor for any company. It holds the key to its existence, development and success. PUBGY, JBL, AMN and AMRK are worth buying, given their rising cash flow.
Elevance Health, Inc. (ELV) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much a $1000 Investment in AMN Healthcare Services Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
AMN Healthcare (AMN) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
AMN Healthcare (AMN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $120.04 in the latest trading session, marking a +1.59% move from the prior day.
Philips' (PHG) Q3 Earnings Down on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q3 top and bottom-line results reflect the negative impact of supply chain constraints, COVID lockdowns in China and the Russia-Ukraine war.
Are Investors Undervaluing AMN Healthcare Services (AMN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Abiomed's (ABMD) Latest Impella Offering Approved by the FDA
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.
Veeva Systems' (VEEV) New Launch to Streamline Clinical Data
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.
Buy These 4 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Scorpio Tankers Inc. (STNG), AMN Healthcare (AMN), Ardmore (ASC) and Lancaster (LANC) are poised to gain.
Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.
Veeva Systems' (VEEV) New Launch to Enhance Digital Trials
by Zacks Equity Research
Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
by Zacks Equity Research
BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.